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The transcription factor C/EBPa is required for granulocytic differentiation of normal myeloid progenitors and is
frequently inactivated in acute myeloid leukemia (AML) cells. Ectopic expression of C/EBPa in AML cells suppresses
proliferation and induces differentiation suggesting that restoring C/EBPa expression/activity in AML cells could be
therapeutically useful. Unfortunately, current approaches of gene or protein delivery in leukemic cells are
unsatisfactory. However, “drug repurposing” is becoming a very attractive strategy to identify potential new uses for
existing drugs. In this study, we assessed the biological effects of candidate C/EBPa-mimetics identiﬁed by
interrogation of the Connectivity Map database. We found that amantadine, an antiviral and anti-Parkinson agent,
induced a monocyte-macrophage-like differentiation of HL60, U937, Kasumi-1 myeloid leukemia cell lines, as indicated
by morphology and differentiation antigen expression, when used in combination with suboptimal concentration of all
trans retinoic acid (ATRA) or Vit D3. The effect of amantadine depends, in part, on increased activity of the vitamin D
receptor (VDR), since it induced VDR expression and amantadine-dependent monocyte-macrophage differentiation of
HL60 cells was blocked by expression of dominant-negative VDR. These results reveal a new function for amantadine
and support the concept that screening of the Connectivity Map database can identify small molecules that mimic the
effect of transcription factors required for myelo-monocytic differentiation.
Introduction
Acute myeloid leukemia (AML) is a blood cancer character-
ized by the expansion of transformed myeloid progenitors which
exhibit a severe block in their ability to differentiate into mature
granulocytes or macrophages; as a result, these cells accumulate
inside the bone marrow interfering with normal hematopoiesis.1
The growth advantage and the differentiation arrest of AML cells
are thought to be caused by aberrant regulation of distinct genes
such as those encoding for a constitutively active tyrosine kinase
and a transcription factor.2,3
In particular, lineage-specific transcription factors are mutated
or functionally inactivated in AML, suggesting a pathogenic link
with the aberrant differentiation of AML cells.4
One such gene, the transcription factor C/EBPa, is required
for granulocytic differentiation of normal myeloid progenitors
and is frequently inactivated in AML cells.5
Structural and non-structural mechanisms are responsible for
inactivation of C/EBPa in AML cells. Mutations of the C/EBPa
gene are detected in approximately 10% of AML patients and fall
into 2 major categories: i) those that abolish the expression of the
p42 protein while retaining expression of p30 (an isoform lacking
the N-terminal transactivation domain); and ii) insertions/deletions
near the basic region (BR)-leucine zipper (LZ) domain that impair
DNA binding activity.6 The importance of the ratio between the
p42 and the p30 isoforms is demonstrated by the observation that
the selective knockout of p42 in mice retaining expression of the
p30 isoform leads to AML formation with high penetrance,7 while
restoring p42 expression suppressed leukemogenesis.8
Expression of C/EBPa can be negatively regulated at the tran-
scriptional level by promoter hypermethylation or by direct tran-
scriptional repression by the AML1-ETO oncoprotein in AML
patients with the 8;21 translocation.9
C/EBPa is also inactivated post-transcriptionally by the
mRNA-binding protein calreticulin that inhibits C/EBPa
mRNA translation in AML patients with the 3;21 translocation
or inv(16) or post-translationally via serine 21 phosphorylation
in AML patients with the FLT3-ITD mutation.10
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Restoring C/EBPa expression/activity could be an effective
strategy to eradicate of AML cells by inhibition of proliferation
and induction of differentiation. Different approaches such as
gene-therapy based on lentiviral vectors, fusion proteins engi-
neered to pass through cellular membranes,11 nanoparticles that
target a TAT-bound protein to specific cell subsets via antibody
binding to surface markers12 are currently under investigation,
but the efficacy of these strategies is unclear. For AML treatment,
recent studies have focused on the development of differentiation
therapies using ATRA combined with epigenetic modifiers13-17;
this approach is based on findings indicating that epigenetic
mechanisms, including DNA methylation, histone methylation
and acetylation, are involved in the repression of RARa expres-
sion in non-APL AML cells.18,19
The Connectivity Map database (www.broadinstitute.org/
cmap/) was generated at the Broad Institute of MIT and Harvard
and it was made available in 2006.20 The first version (Build 01)
was built by assessing the effects of 164 small-molecule perturba-
genes (FDA-approved drugs and nondrug bioactive “tool” com-
pounds) on the transcriptome of 5 cancer cell lines.
Subsequently, this database was expanded to 1,309 FDA-
approved small molecules generating 6,100 gene expression pro-
files from 7,056 microarray chips.
Given the large amount of collected data, the real challenge
for an optimal use of the cMap is data analysis. In the last few
years, uploaded data were re-elaborated by different groups in
order to make such data more usable and different version of the
cMap such as MANTRA,21,22 sscMap,23 cudaMap24 were
developed.
Several studies have demonstrated that interrogation of the
Connectivity Map database could provide a powerful tool to
elucidate the mechanism of action of small molecules20,25,26 or
to reveal new functional connections with known com-
pounds.27,28 However, the most important potential application
of cMap analysis is “drug repurposing,” namely the discovery
that known drugs may have entirely new therapeutic targets.
Examples of “drug repurposing” were reported in acute lymphoid
leukemia (ALL),26 skeletal muscle atrophy (SMA),29 inflamma-
tory bowel disease (IBD),30 breast cancer,31 and hepatocellular
carcinoma.32
In the present study, we interrogated the cMap database to
identify small molecules that may mimic the biological effects of
the transcription factor C/EBPa in AML cells.
Results
Identification of candidate C/EBPa-mimetics by
interrogation of the Connectivity Map database
To identify small molecules (“perturbagenes”) that may
mimic the biological effects induced by ectopic expression of C/
EBPa in myeloid leukemia cells, we queried the Connectivity
Map database with a subset of C/EBPa-regulated genes (“C/
EBPa gene signature”) identified through transcriptional profil-
ing of K562 cells expressing a tamoxifen-regulated C/EBPa-ER
chimeric protein.33
In particular, the Connectivity Map database was queried with
a subset of up-regulated and down-regulated genes representing
those associated with myeloid differentiation (“up-tags”) or inhi-
bition of cell proliferation (“down-tags”) (Table 1). Using this
approach, we identified 8 compounds displaying positive connec-
tivity with the “C/EBPa gene signature” (Table 2).
Table 1. 43-gene signature of differentially expressed genes in K562 cells ectopically expressing the C/EBPa-ER chimera. Upregulated (left column) and
down-regulated (right column) selected genes are listed in alphabetical order
Up-regulated genes Downregulated genes
Acyl-CoA synthetase long-chain family member 1 Ankyrin 1
Annexin A1 CD69
C/EBPa Cyclin D1
C/EBPg Cyclin D2
C/EBPd Cyclin-dependent kinase 6 (CDK 6)
C/EBPe Cyclin-dependent kinase inhibitor 1C (CDKN1C)
CD64 GATA2
Chitinase-3-like protein 1 (CHI3L1) Growth factor indipendent 1B (GFI-1 B)
CXCR4 HOXC4
Cyclin G2 Interleukin-10a receptor (IL10a-r)
FUT4 Interleukin-2 receptor g (IL2-rG)
GCSF-receptor (GCSF-r) JUN D
Interleukin-1 receptor (IL1-r) Keratin 19 (K19)
Interleukin-4 receptor (IL4-r) KIT
Interleukin-6 receptor (IL6-r) Leptin receptor (LEP-r)
Matrxi metalloprotease 8 (MMP8) Myc
Monocyte to macrophage differentiation-associated Perforin 1
Myeloperoxidase (MPO) PIM2
Neutrophil elastase (ELANE) STAT5 A
Plasminogen activator, urokinase receptor (PLAUR) T cell receptor b constant 1
S100 calcium binding protein A8
Secretory leukocyte peptidase inhibitor (SLP1)
TNFa-induced protein 6 (TNFAIP6)
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Since little or no information is available on the effective dose
of most compounds, different drug concentrations were tested in
order to identify an appropriate dose (neither toxic nor ineffec-
tive) for each compound. Initially, cells were treated with the
drug concentration utilized to generate the Connectivity Map’s
data (Table 2). Proliferation was assessed after treatment for 24,
48, 72 hours and 6 days; since most compounds had no appreci-
able effects on morphology, they were used at concentrations
higher of those utilized to generate the cMap database (Fig. S1).
Based on the results of these assays, rolipram and pilocarpine
were excluded from further studies because they had no effect
even at a very high concentration; we excluded also kawain
because morphological analysis (data not shown) showed that
growth inhibition was due to cytotoxicity. Finally, griseofulvin
was also excluded because at the concentration reported in the
cMap database, it strongly inhibited proliferation. Morphological
analysis (data not shown) revealed that the effect was due to a
massive block of cytokinesis. However, at lower concentrations,
there was neither inhibition of proliferation nor block of
cytokinesis.
Moreover, ATRA and PCPA, 2 additional drugs identified by
our screening, were not further analyzed because it is well estab-
lished that they promote granulocytic differentiation in leukemic
cells.34-37
In summary, after these analyses, diperodon, a local anes-
thetic, and amantadine, an anti-viral and anti-Parkinson drug,
were selected for further studies. On the assumption that, like
PCPA,38 diperodon and amantadine may not be able to induce
differentiation when used alone, experiments were also per-
formed upon co-treatment with ATRA, used at a suboptimal
concentration insufficient for granulocytic differentiation.
Diperodon treatment inhibits proliferation but has modest
effects on differentiation of HL60 cells
After preliminary experiments, we selected 40mM as the opti-
mal diperodon concentration for treatment of HL60 cells. There-
fore, proliferation and differentiation of HL60 cells was assessed
after treatment with ATRA alone (10nM), diperodon alone
(40mM) or the ATRA-diperodon combination (10nM and
40mM, respectively). Treatment with ATRA alone slightly
reduced proliferation of HL60 cells, whereas treatment with
diperodon alone or with the ATRA-diperodon combination was
much more effective; in particular, co-treated cells exhibited a
60% decrease of proliferation at day 6 (Fig. 1A).
To assess if reduced proliferation was associated with induc-
tion of differentiation, the immunophenotype of ATRA and/or
diperodon-treated cells was evaluated at 3 and 6 d post-treatment
by staining with anti-CD11b, anti-CD14, anti-CD15 and anti-
CD163 antibodies which detect common markers of granulo-
cytic and monocytic differentiation. At day 3, we observed a sta-
tistically significant increase in CD11b levels in cells co-treated
with ATRA C diperodon compared to untreated cells or to cells
treated with ATRA or diperodon only. Percentage of CD11b
positivity and differences between treatments were similar at day
6 (Fig. 1B; Fig. S2A).
Compared to untreated cells or cells treated with ATRA alone,
treatment with diperodon, either alone or in combination with
ATRA, led to higher CD15 expression both at day 3 and day 6;
however, CD15C positivity was only approximately 20% and
most changes are not statistically significant (Fig. 1C, Fig. S2B).
CD14 positivity was very similar to that of CD15, exhibiting a
slight increase in diperodon-treated cells, at both time points.
However, CD14 levels were very low and the differences were
not significant except for the ATRA C diperodon versus the
diperodon treatment at day 3 (Fig. 1D; Fig. S2C).
Finally, we also assessed the expression of the monocytic dif-
ferentiation antigen CD163 (Fig. 1E; Fig. S2D). At day 3,
CD163 levels were slightly up regulated by treatment with diper-
odon only, or upon co-treatment with ATRA; however, the levels
of expression were quite low. At day 6, the various treatments did
not induce significant changes in CD163 levels.
To further characterize the differentiation of diperodon-
treated HL60 cells, we assessed the expression of CD11b, CD14
and CD163 by real-time Q-PCR. In the case of CD11b, mRNA
levels do not correlate with cytofluorimetric values because the
highest expression of CD11b mRNA was detected in cells treated
for 72 h with ATRA only (Fig. 2A), while levels of the surface
protein were higher in cells co-treated with ATRA C diperodon.
Conversely, CD14 mRNA levels were higher in diperodon-
treated cells, in good agreement with flow cytometry data
(Fig. 2B). Likewise, expression of CD163 was also induced by
treatment with diperodon only (Fig. 2C).
The differentiation-inducing effect of a compound is best
evaluated by morphological analysis; thus, we assessed the mor-
phology of May-Gr€unwald-Giemsa-stained cytospins of treated
HL60 cells. At day 6, ATRA-treated cells maintained a blast-like
morphology with some metamyelocytes and rare band cells; this
result was expected because cells were treated with a concentra-
tion of ATRA 100-fold lower than the standard concentration
used to induce granulocytic differentiation. Cells grown in pres-
ence of diperodon only showed an increased cytoplasm but did
not display hallmarks of differentiation. In contrast, cells treated
with ATRA C diperodon exhibited a heterogeneous morphology
characterized by increased cytoplasm and bean-shaped nuclei;
however, the morphology did not allow a clear distinction
between monocyte-macrophage- or metamyelocyte-like cells and
Table 2. Rank-ordered list of compounds after cMap query and post-proc-
essed selection. The table shows the dose used to generate the signature of
differentially expressed genes for every small-molecule, the connectivity
score and its up-score and down-score components
cMap molecule
name
cMap
dose
connectivity
score
up-
score
down-
score
diperodon 9 mM 0.91 0.364 ¡0.249
tranylcypromine (PCPA) 24 mM 0.905 0.331 ¡0.279
rolipram 15 mM 0.887 0.33 ¡0.267
griseofulvin 11 mM 0.884 0.357 ¡0.239
pilocarpine 15 mM 0.853 0.352 ¡0.222
kawain 17 mM 0.821 0.416 ¡0.136
amantadine 10 mM 0.81 0.291 ¡0.254
tretinoin (all-trasn
retinoic acid, ATRA)
1 mM 0.807 0.267 ¡0.277
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a large number of undifferentiated blasts were still present
(Fig. 3A).
In summary, diperodon is unable induce terminal differentia-
tion as indicated by morphological analyses; however, it appears
to have a partial effect based on changes in the expression of
some monocyte/macrophage differentiation markers.
Treatment with amantadine promotes the monocyte-
macrophage-like differentiation of HL60 cells
Preliminary results indicated that amantadine used at a con-
centration of 200mM had cytostatic but not cytotoxic effects.
Thus, HL60 cells were cultured for 6 d in presence of amanta-
dine (200mM), ATRA (10nM), or the combination ATRA-
amantadine (10nM and 200mM, respectively). Compared to
untreated cells, all 3 treatments caused a marked growth inhibi-
tion. At day 3 post-treatment, there was no difference in the
number of cells cultured in the presence of ATRA C amantadine
or amantadine alone. By contrast, at day 6, the ATRA-
amantadine co-treatment had a clear
cytotoxic effect with cell counts lower of
those at day 0 (Fig. 4A).
To assess if these effects on cell prolif-
eration correlated with induction of ter-
minal differentiation, we evaluated the
immunophenotype of drug-treated cells.
Thus, 3 and 6 d after treatment, cells
were tested for expression of the surface
markers CD11b, CD15, CD14 and
CD163. As expected, treatment with
ATRA alone induced a marked increase
in CD11b positivity, at day 3 and 6, but
the co-treatment further increased the
number of cells expressing this marker
(approximately 20% at both time-points)
(Fig. 4B; Fig. S3A). Expression of
CD15 was upregulated only in cells
treated with amantadine, alone or with
ATRA; in particular, co-treated cells
exhibited a marked increase in CD15 lev-
els at day 6 (Fig. 4C; Fig. S3B). The
trend of CD14 positivity was similar to
that of CD15: CD14 levels were barely
detectable in untreated and ATRA-
treated cells, while treatment with aman-
tadine, alone or with ATRA, induced an
increase in positivity at 3 and 6 d How-
ever, the co-treatment induced a marked
increase in CD14 surface levels only at
day 6 (Fig. 4D; Fig. S3C). Expression of
the CD163 antigen was barely detectable
in untreated and ATRA-treated cells
while treatment with amantadine, with
or without ATRA, caused a slight
increase at day 3. By contrast, expression
of CD163 was strongly induced at day 6
by the ATRA C amantadine co-treatment (Fig. 4E; Fig. S3D).
The effects of amantadine were further investigated by
assessing CD11b, CD14 and CD163 mRNA levels 3 d post-
treatment. Consistent with flow cytometry data, CD11b
mRNA levels were up-regulated in cells co-treated with ATRA
and amantadine and, to a lesser extent, in cells treated with
ATRA only. Compared to untreated cells, even cells treated
with amantadine only displayed enhanced expression of
CD11b, but the relative increase is considerably lower than
that induced by the other treatments (Fig. 5A). Expression of
CD14 mRNA was also consistent with cytofluorimetric data:
treatment with amantadine only induced an increase in CD14
mRNA levels but the increase was higher in the co-treated
samples (Fig. 5B). Expression of CD163 mRNA was low in
untreated and ATRA-treated cells; by contrast, such levels
were markedly upregulated in cells treated with amantadine
(alone or with ATRA) (Fig. 5C). Once again, the co-treatment
with ATRA was more effective than amantadine only in
inducing the increase in CD163 expression.
Figure 1. Effect of diperodon, ATRA, or the diperodon-ATRA combination on the proliferation and
differentiation of HL60 cells. Proliferation (A) and differentiation marker expression (CD11b,CD15,
CD14, and CD163) by ﬂow cytometry analysis (B–E), of HL60 cells treated with diperodon, ATRA or
the diperodon-ATRA combination. Data are reported as mean § SD of three independent experi-
ments. Statistical signiﬁcance was calculated using unpaired, 2-tailed Student’s t test and considered
signiﬁcant with p < 0 ,05. “NS” indicates not statistically signiﬁcant differences.
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To confirm that treatment with amantadine induced a mono-
cyte-macrophage-like differentiation, cell morphology was evalu-
ated by May–Gr€unwald-Giemsa staining of cytospin
preparations (Fig. 3B). Cells grown in presence of amantadine
only displayed a non-uniform morphology characterized by the
presence of leukemic blasts and of monocyte-macrophage-shaped
cells (approximately 20 and 25% in each field at day 3 and 6,
respectively). In sharp contrast, cells co-treated with ATRA and
amantadine exhibited a uniform morphology characterized by
the presence of macrophage-shaped cells (approximately 50 and
95% in each field at day 3 and 6, respectively), single or in aggre-
gates, with features of apoptosis such as pyknotic nuclei.
Effects of amantadine treatment on the cell cycle of HL60
cells
The effects of amantadine on the cell cycle of HL60 cells were
also evaluated. DNA-content analysis (Supplementary Fig. 4A)
revealed that, at 48 hours, co-treatment of ATRA and amanta-
dine induced a 15% increase in G1 phase cells and a 18%
decrease in S phase cells, compared to untreated cells. These dif-
ferences were even more evident at 72 hours, and were confirmed
by 50-Bromodeoxyuridine (BrdU) labeling (Fig. S4C). Of inter-
est, amantadine alone induced a significant increase in the num-
ber of G1 phase cells and reduced the number of S phase cells
during the first 3 d of treatment; at these time points treatment
with ATRA alone was much less effective.
Finally, apoptotic, subG1 cells were also detected at day 6, but
only in the co-treated samples; this finding was confirmed by
Annexin V staining (Fig. S4B).
Treatment with amantadine induces an increase in the
expression of Vitamin D receptor (VDR), a master regulator
of monocytic differentiation
To investigate mechanisms potentially responsible for the
amantadine-dependent induction of monocytic differentiation,
we analyzed the expression of PU.1 and VDR, 2 transcription
factors with essential roles in monocytic differentiation.
First, we assessed levels of PU.1 mRNA at 24, 48 and
72 hours post-treatment (Fig. 6A).The ATRA-amantadine co-
treatment significantly enhanced PU.1 mRNA expression, both
at 48 and 72h; however, the levels of the protein did not change
at day 3 or even at day 6 post-treatment (Fig. 6C). These find-
ings were confirmed by densitometric analysis which shows no
statistically significant differences between the various treatments,
at any time point (Fig. 6E).
By contrast, treatment with amantadine, alone or with ATRA,
induced an increase in VDR levels. In particular, expression of
VDR mRNA is significantly increased at 72 hours in cells co-
treated with ATRA and amantadine (Fig. 6B). Instead, increased
expression of VDR protein is not only detected in cells treated
with both compounds but also in cells treated with amantadine
only for 3 or 6 d (Fig. 6D and F).
To determine whether expression of a functional VDR is
required for the monocyte-macrophage-like differentiation
induced by amantadine, we generated 2 derivative HL60 cell
lines: one expressing a truncated version of the VDR lacking the
AF2 transactivation domain (dominant negative VDR) and one
carrying only the empty vector (LXIDN) (Fig. 7A). The trun-
cated VDR acts as a dominant negative of the endogenous VDR
blocking its activity, as previously shown in the U937 cell line by
Gemelli and colleagues.38
Both derivative HL60 cells lines were left untreated or cul-
tured for 6 d in presence of amantadine (200mM), ATRA
Figure 2. Effect of diperodon, ATRA, or the diperodon-ATRA combina-
tion on mono-macrophage differentiation marker expression in HL60
cells. (A–C) mRNA levels of CD11b, CD14 and CD163 detected by real
time PCR in HL60 cells treated (72 h) with diperodon, ATRA or the diper-
odon-ATRA combination. Expression of the housekeeping gene HPRT
was used as internal control. Results are reported as normalized-fold vari-
ation over untreated cells (NT) taken as 1. Graphs are representative of 3
independent experiments.
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(10nM), or the combination ATRA-
amantadine (10nM and 200mM, respec-
tively). Upon treatment for 3 or 6 days,
empty vector-transduced cells exhibited
the expected decrease in cell number
(Fig. 7B). By contrast, cells over-express-
ing the dominant-negative VDR showed
a slight, but not statistically significant,
decrease in cell proliferation only at day
6 (Fig. 7C).
Flow cytometry analysis of HL60
derivative cell lines revealed that levels of
the monocyte/macrophage surface anti-
gens CD14 and CD163 increased, espe-
cially at day 6, upon co-treatment with
ATRA and amantadine or treatment
with amantadine only of empty vector-
transduced cells (Fig. 7D and D; Fig.
S5A and C). Such an increase was
blocked in HL60 cells expressing domi-
nant-negative VDR (Fig. 7F and G,
Fig. S5B and D).
These results demonstrate that block-
ing the activity of VDR strongly inhibits
the differentiation-promoting effect of
amantadine.
Treatment with amantadine
enhances vitamin D3-dependent
monocyte/macrophage differentiation of
U937 and Kasumi-1 cells
The effect of amantadine as pro-
moter of monocytic differentiation was
not limited to the model of ATRA-
treated HL60 cells; in the model of
vitamin D3-induced monocytic differ-
entiation of U937 cells, co-treatment
with vitamin D3 and amantadine
enhanced the expression of CD11b,
CD14, and CD163, compared to
Figure 3. Morphology of of HL60 cells treated with diperodon, amantadine, ATRA or the diperodon-
ATRA or the amantadine-ATRA combination in HL60 cells. Light microscopy images of May–
Gr€unwald-Giemsa stained HL60 cells treated for 6 d with diperodon, ATRA, or the diperodon-ATRA
combination (A) or with amantadine, ATRA, or the amantadine-ATRA combination (B). Original mag-
niﬁcation 40£.
Figure 4. Effect of amantadine, ATRA, or the
amantadine-ATRA combination on the prolif-
eration and differentiation of HL60 cells. Pro-
liferation (A) and differentiation marker
expression (CD11b,CD15, CD14, and CD163)
by ﬂow cytometry analysis (B–E), of HL60
cells treated with amantadine, ATRA or the
amantadine-ATRA combination. Data are
reported as mean § SD of three indepen-
dent experiments. Statistical signiﬁcance was
calculated using unpaired, 2-tailed Student’s
t test and considered signiﬁcant with P < 0
,05. “NS” indicates not statistically signiﬁcant
differences.
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treatment with vitamin D3 or amantadine only (Fig. 8A–D;
Fig. 6A–C). Such an effect correlated with an increase in
VDR expression which was more evident in U937 cells co-
treated with vitamin D3 and amantadine for 6 d (Fig. 8E).
We also evaluated the effects of amantadine in the Kasumi-1
cell line which is another widely used model of acute myeloblastic
leukemia. Although treatment with amantadine did not induce
an increase in the expression of CD163 (Fig. S7D and H), levels
of CD11b and especially CD14 were strongly upregulated by the
vitamin D3 and amantadine co-treatment (Fig. S7B, C, F, G).
Finally, the co-treatment also induced inhibition of proliferation
and enhanced expression of VDR (Fig. S7A and E). Collectively,
these data indicate that amantadine cooperates with vitamin D3
in promoting the monocytic differentiation of Kasumi-1 cells.
Discussion
In this study, we interrogated the Connectivity Map database
with a gene signature of genes up-regulated and downregulated
upon activation of C/EBPa in K562 cells to identify bioactive
molecules potentially mimicking the biological effects of C/
EBPa. The rationale behind this approach rests on the assump-
tion that compounds that mimic the effects of C/EBPa might
have therapeutic effects in AML, since C/EBPa inhibits cell pro-
liferation and is a potent inducer of differentiation upon ectopic
expression in myeloid blast crisis CML cells.39,40
Moreover, C/EBPa is structurally inactivated or non-func-
tional in most AML subtypes,6,9-11 further reinforcing the notion
that “C/EBPa mimetics” may have anti-leukemia effects.
Interrogation of the Connectivity Map database has been uti-
lized to identify small molecules that modulate drug-induced
apoptosis or enzyme inhibitors26-28 as potential anti-cancer
agents, but has not been used to identify compounds that mimic
the activity of a transcription factor and, doing so, exert anti-leu-
kemia effects.
In support of the validity of our approach, we identified
ATRA and tranylcypromine (PCPA) as potential “C/EBPamim-
etics;” ATRA is a well known inducer of promyelocytic leukemia
differentiation34 and PCPA is a histone H3K4 and K9 demethy-
lase inhibitor that collaborates with ATRA in promoting differ-
entiation of AML cells.41 Thus, it is not surprising that these
agents may activate a gene expression program similar to that
induced by C/EBPa.
In addition to ATRA and PCPA, we identified other com-
pounds which we did not expect that may function as “C/EBPa
mimetics” based on their known mechanism(s) of action.
We selected for further studies diperodon, a local anesthetic,
and amantadine, an antiviral and anti-Parkinson drug. Both
drugs failed to induce C/EBPa expression (not shown), indicat-
ing that any “C/EBPa-mimetic” effect would not be due to
increased C/EBPa levels.
However, set-wise comparisons and GSEA revealed statisti-
cally significant similarities in the genes regulated by C/EBPa
and amantadine treatment. In particular, the similarity was more
evident in the upregulated genes; in this geneset, approximately
10% (including established C/EBPa targets such as neutrophilic
elastase and IL4-R) showed at least a 1.fold5- increase (Fig. S8).
Treatment with diperodon inhibited HL60 cell proliferation
but had only a modest and transient effect on the expression of
the monocyte/macrophage differentiation markers CD14 and
CD163 (Figs. 1 and 2; Fig. S2); not surprisingly, these changes
correlated only with subtle morphological alterations such as an
Figure 5. Effect of amantadine, ATRA, or the amantadine-ATRA combina-
tion on mono-macrophage differentiation marker expression in HL60
cells. (A–C) mRNA levels of CD11b, CD14 and CD163 detected by real
time PCR in HL-60 cells treated (72 h) with amantadine, ATRA or the
amantadine-ATRA combination. Expression of the housekeeping gene
HPRT was used as internal control. Results are reported as normalized-
fold variation over untreated cells (NT) taken as 1. Graphs are representa-
tive of 3 independent experiments.
2584 Volume 14 Issue 16Cell Cycle
D
ow
nl
oa
de
d 
by
 [A
 Z
 U
SL
 R
eg
gio
 E
mi
lia
] a
t 0
7:2
0 2
5 A
ug
us
t 2
01
5 
enlarged cytoplasm and a segmented or peripheral nucleus in a
minority of cells, especially after treatment with the diperodon/
ATRA combination (Fig. 3A).
By contrast, the effects induced by treatment with amantadine
were much more pronounced, especially upon co-treatment with
ATRA. In particular, HL60 cells treated with the ATRA/amanta-
dine combination proliferated less than untreated cells or those
treated with amantadine or ATRA only (Fig. 4, Fig. S3). More-
over, expression of monocyte/macrophage differentiation anti-
gens was markedly increased in amantadine/ATRA co-treated
cells (Figs. 5 and 6) and such an increase correlated with the
appearance of clear morphological features of monocyte/macro-
phage differentiation (Fig. 3B).
Of greater interest, treatment with amantadine led to an
increase in the expression of VDR and such an increase
appears to be biologically relevant since monocyte/macrophage
differentiation induced by co-treatment with ATRA and
amantadine was completely blocked by expression of a domi-
nant-negative VDR lacking the transactivation domain
(Fig. 7; Fig. S5).
Amantadine is an FDA-approved anti-viral and anti-Parkin-
son drug; one of its mechanisms of activity is to function as weak
inhibitor of the NMDA-type glutamate receptor.42 However,
this mechanism of action is unlikely to explain the differentia-
tion-promoting effects described here.
A recent study has shown that treat-
ment with amantadine enhanced the
cytotoxic effects of the BCR-ABL tyro-
sine kinase inhibitor imatinib via
increased release of calcium from the
endoplasmic reticulum (ER) by inhibi-
tion of the influx transporter hOCT1.43
However, ER stress appears more likely
to impair than to promote macrophage
differentiation.44
Our findings suggest that the differen-
tiation-promoting effects of amantandine
may depend on its ability to induce an
increase in the expression of VDR.
The existence of ligand independent
activation has been clearly demonstrated
for a number of nuclear receptors,
including VDR,45 suggesting that this
type of regulation could probably play a
role in the monocyte/macrophage differ-
entiation induced by amantadine. In
support to this hypothesis, vitamin D3-
independent activation of VDR has been
sometimes observed in association with
an increase of its expression,46 exactly as
in our studies.
There is evidence that, as shown for
other nuclear receptors, chemical com-
pounds unrelated to vitamin D3 can also
bind the VDR, although at considerably
higher concentrations, mimicking its bio-
logical effect.47 Therefore, a molecular docking analysis, carried
out by a computational approach and validated through a com-
petitive binding assay, could determine if there is a direct interac-
tion between amantadine and VDR.
In summary, we have identified 2 compounds with known
mechanisms of action unpredicted to affect myeloid differentia-
tion that cooperate with ATRA and appear to re-direct its tran-
scription-regulatory effect toward the induction of monocyte/
macrophage differentiation. Although we did not identify yet
compounds that mimic exactly the biological effects of C/EBPa,
further interrogation of the Connectivity Map database seems a
promising approach to identify such agents.
Materials and Methods
Connectivity Map analysis
The Connectivity Map was queried with a “C/EBPa sig-
nature” obtained by transcription profiling of C/EBPa-ER-
expressing K562 cells.33 As described by Lamb and colleagues,20
a nonparametric, rank-based pattern matching strategy, based on
Kolmogorov-Smirnov statistics, was used in the calculation of
the Connectivity Score for each drug/small-molecule in the
database.
Figure 6. Effect of amantadine, ATRA, or the amantadine-ATRA combination on PU.1 and VDR
expression in HL60 cells. Levels of PU.1 and VDR mRNA (A, B) or protein (C, D) detected by real time
PCR and western blotting, respectively, in untreated or drug-treated HL-60 cells; (E, F) Densitometric
analysis from 2 combined experiments. Expression of Grb2 was detected as loading control. Statisti-
cal signiﬁcance was calculated using unpaired, 2-tailed Student’s t test and considered signiﬁcant
with p < 00.05. “NS” indicates not statistically signiﬁcant differences.
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Data were evaluated according to the
following criteria: i) we considered only
data generated by treatment of the HL60
cell line, which is a widely used model of
all trans retinoic acid (ATRA)-induced
differentiation of acute promyelocytic
leukemia cells; ii) we selected only com-
pounds with connectivity scores between
C0,8 and C1; as, to date, there is no sta-
tistical method that can correlate the con-
nectivity score with biological relevance,
we arbitrarily set the threshold at C0,8 in
order to investigate a reasonable number
of compounds; iii) we focused on the up-
score of the compounds selected so far. A
high positive up-score (a component of
the connectivity score) indicates that the
genes up-regulated by the corresponding
molecule strongly correlate with those
upregulated in the query signature (up-
tag list). Then, we set an arbitrary thresh-
old of C0.29 ad re-ordered the select
compounds based on their up-score.
Finally, we analyzed the list of up-regu-
lated genes modulated by each com-
pound that passed these selection criteria.
For each gene, we considered the param-
eters “score” and “amplitude” which,
approximately, indicate how much a
gene is upregulated and excluded pertur-
bagenes for which the up-regulated genes
have low or negative values of “score”
and “amplitude.”
Set-wise and GSEA comparisons
The HL60 amantadine and dipero-
don cMap microarray profiles were
compared with C/EBPa-induced genes
in 2 ways, first using a set wise compar-
ison to test for similarity among the
topmost upregulated genes, and second
using gene set enrichment analysis
(GSEA), which is sensitive to subtle
but concerted changes in gene expres-
sion. For compatibility between the
cmap profiles, generated using the Affymetrix GeneChip HG-
U133A microarrays, and the C/EBPa data, generated on the
Affymetrix GeneChip HG-U133plus2 platform, analysis was
performed on the 22283 probesets common between the 2
platforms. C/EBPa-induced genes were defined with mini-
mum 1.fold5- change and differential expression P-value cut-
off of 0.05. While these limits define a set of 663 unique
genes when limited to the 22283 HG-133A probesets, the
cmap data is represented as ranked lists so equivalent fold
changes and P-values cannot be applied. Instead, gene subsets
of roughly equivalent size were defined for set-wise
comparisons, using the top 500 ranked genes in both the
amantadine and diperodon profiles. Overlap between C/
EBPa-induced genes and the 500 most upregulated genes in
the amantadine and diperodon profiles was visualized using
Venn diagrams and tested for significance using the hypergeo-
metric P-value. GSEA was then used to evaluate the similarity
between the C/EBPa-induced gene signature and the amanta-
dine and diperodon profiles in a different manner, using the
entire ranked list of HGU133A probesets from the cmap data
to evaluate the positive enrichment of C/EBPa-induced genes
along those ranked lists. GSEA was performed using the
Figure 7. Effect of amantadine, ATRA, or the amantadine-ATRA combination on the proliferation and
differentiation of empty vector-transduced or dominant negative VDR-expressing HL60 cells. West-
ern blot (A) of VDR expression (endogenous or dominant-negative VDR) in HL60 cells transduced
with the empty vector or with dominant-negative VDR. Levels of Grb2 were measured as loading
control. Proliferation (B, C) and differentiation marker expression (CD14 and CD163) by ﬂow cytome-
try analysis (D–G), of empty vector-transduced (B, D, E) or dominant -negative VDR-expressing (C, E,
F) HL-60 cells treated with amantadine, ATRA or the amantadine-ATRA combination. Data are
reported as mean § SD of three independent experiments. Statistical signiﬁcance was calculated by
unpaired, 2-tailed Student’s t test and considered signiﬁcant with p < 0 ,05. “NS” indicates not statis-
tically signiﬁcant differences.
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“classic” enrichment statistic, which is most suitable for the
cmap ranked data, consisting of integers from 1 to 22283.
Normalized enrichment scores and P-values were generated by
GSEA as previously described.48
Cell culture and drugs
U93 and Kasumi-1 cell lines and parental and derivative
HL60 cell lines were cultured in RPMI 1640 supplemented with
100 U/ml penicillin and 0,1 mg/ml streptomycin (Euroclone S.
p.A, Milan, Italy), 10% FBS (Sigma-Aldrich, Oakville, ON,
Canada). Derivative HL60 cell lines (carrying the VDR domi-
nant-negative LVDRDAF2IDN plasmid and defined “dominant
negative VDR;” or the empty vector plasmid LXIDN and defined
as “empty vector”) were established as described.38
Diperodon, rolipram, griseofulvin, pilocarpine, amanta-
dine, ATRA and 1,25(OH)2D3 (Vitamin D3) were purchased
from Sigma-Aldrich (Saint Louis, MO, USA) and stored as
indicated by the manufacturer. Kawain was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Due to lack of
information regarding compound stability, freshly made stock
solutions were prepared for each experiment, except for
ATRA.
Cell proliferation and differentiation
assays
For preliminary screening of the 6
compounds identified by cMap analysis,
HL60 cells were seeded at 1.5£105 cells/
ml and treated with each compound,
firstly, at the concentration reported in
the cMap database. Subsequently, other
concentrations were tested, based on the
results obtained. To evaluate the effects
of the small molecules on proliferation,
cells were treated for 24, 48, 72 hours
and 6 d and counted by trypan blue
exclusion (Gibco, Life Technologies,
Carlsbad, CA, USA).
For further analysis of selected com-
pounds, parental and derivative HL60
cells were seeded at 1.5£105 cells/ml and
left untreated or treated with ATRA
(10nM), ATRA C diperodon (10 nM
and 40mM, respectively) or amantadine
(200mM), or diperodon (40mM) or
amantadine (200mM) only. Three and 6
d post treatment, cells were counted by
trypan blue exclusion and differentiation
was evaluated by May-Gr€unwald-Giemsa
staining (Sigma-Aldrich) of cytospins
and by flow cytometry analysis of differ-
entiation markers.
U937 and Kasumi-1 cells were seeded
at 1£105 cells/ml and left untreated or
treated with Vitamin D3 (10¡8M), Vita-
min D3 C amantadine (10¡8M and 200mM, respectively) or
amantadine (200mM) only. Three days post treatment, U937
cells were diluted 1:5 and drugs were added at the appropriate
concentrations. Three and/or 6 d after the beginning of the treat-
ment, cells were counted by trypan blue exclusion and differenti-
ation was evaluated by flow cytometry analysis of differentiation
marker expression.
Flow cytometry
For cell cycle analysis, the hypotonic propidium iodide
method49 was used. To determine the number of cells in S phase,
a 50- Bromodeoxyuridine (BrdU) incorporation assay was carried
out, as preiously reported,50 in cells treated for 48 hours.
Differentiation of treated cells were assessed by evaluating the
levels of surface markers specific for granulocytic and monocytic
differentiation, by use of: anti-CD11b (PE rat anti-mouse
CD11b, clone M1/70, cat: 557397, BD-PharMingen, San
Diego, CA, USA), anti-CD15 (PE-Cy mouse anti-human
CD15, clone Hl98, cat: 560827, BD Pharminogen), anti-CD14
(PE mouse anti-human CD14, cat:555398, BD Pharminogen)
and anti-CD163 (PE mouse anti-human CD163, cat: 556018,
BD Pharminogen) antibodies.
Three£105 HL60, U937 and Kasumi-1 cells were harvested
for each condition, washed in PBS C 2% FBS, resuspended in
Figure 8. Effect of amantadine, Vitamin D3, or the amantadine-Vitamin D3 combination on prolifera-
tion, differentiation, and VDR expression of U937 cells. Proliferation (A), ﬂow cytometry analysis of
differentiation marker expression (CD11b, CD14, and CD163) (B–D), and VDR levels (E) of U937
treated with amantadine, Vitamin D3 or the amantadine-Vitamin D3 combination. Data are reported
as mean § SD of three experiments. Statistical signiﬁcance was calculated using unpaired, 2-tailed
Student’s t test and considered signiﬁcant with p < 0 ,05. “NS” indicates not statistically signiﬁcant
differences. In (E), expression of Grb2 was monitored as loading control.
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500ml of PBS C 2% FBS and incubated with the respective anti-
body for 1 hour at 4C avoiding light exposure. Then, cells were
washed twice in PBS C 2% FBS, resuspended in 500ml of PBS
and analyzed by Coulter Epics XL-MCL (Coulter Corporation,
Miami, FL, USA).
Data are reported as the mean of the value obtained subtract-
ing the “blank” value (auto-fluorescence baseline) to the gate
measurements § SD of two or 3 independent experiments.
Real-Time quantitative PCR
Treated cells were collected at 24, 48 and 72h and total RNA
was isolated using RNeasy Mini kit (Qiagen, Valencia, CA,
USA) and reverse transcribed by the High Capacity cDNA
Reverse Transcription kit (ABI, Life Technologies), both per-
formed following manufacturer’s instructions. The resulting
cDNA was used as PCR template. All reactions were carried out
in triplicate and total RNA was extracted from 2 or 3 indepen-
dent experiments. RT-qPCR was performed using the Go Taq
PCR Mater Mix (Promega, Madison, WI, USA) on a MyIQ5
thermocycler (BioRad, Hercules, CA, USA) and quantified using
MyIQ5 software (Bio-Rad). Levels of HPRT were monitored as
internal control to normalize input cDNA. Data were analyzed
with DCt method.
Primers used are as follows: CD11b: Fw 50-CGCCAT-
CATCTTACGGAACC-30, Rv 50-CTGCCTGAACATCGC-
TACC-30; CD14: Fw 50-AAGCACTTCCAGAGCCTGTC-30,
Rv 50-TCGTCCAGCTCACAAGGTTC-30;CD163: Fw 50-
ATAACTGTGACCATGCTGAGG-30, Rv 50-ACATTCAGT-
GACTCCATCTACC-30; PU.1: Fw 50-GCGTGCAAAAT
GGAAGGGTT-30, Rv 50-GGCTATGGCTCTCCCCATCAC-
30;VDR: Fw 50- CCAGTTCGTGTGAATGATGG ¡30, Rv
50- AGATTGGAGAAGCTGGACGA ¡30;HPRT: Fw 50-
AGACTTGCTTTCCTTGGTCAGG-30; Rv 50-GTCTGGCT
TATATCCAACACTTCG-30.
Western blot analysis
For Western blotting, cells were lysed (2 £ 105 cells/20mL in
Laemmli buffer) and proteins of interest were detected with
anti-PU.1 rabbit polyclonal antibody (SC-352; Santa Cruz Bio-
technology, Santa Cruz, CA), anti-Vitamin D receptor rabbit
monoclonal antibody (EPR4552; AbCam, Cambridge, UK) or
anti-GRB2 monoclonal antibody (610112; BD Transduction
Laboratories, Lexington, KY). For densitometric analysis of
expression levels, bands corresponding to PU.1, VDR and Grb2
as loading control, were scanned and analyzed with ImageJ Soft-
ware (National Institutes of Health).
Statistical analyses
Data (presented as the mean § SD of two or 3 independent
experiments) were analyzed for statistical significance by the
unpaired, 2-tailed Student’s t test. P values less than 0.05 were
considered statistically significant.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Funding
This work was supported by grants from Fondazione Cassa di
Risparmio di Vignola (FCRV) and National Cancer Institute
(NCI) RO1 CA 167169 to BC. GM is supported by a post-doc-
toral fellowship of the Associazione Italiana Ricerca sul Cancro
(AIRC). SC is supported by a fellowship from the “Fondazione
Umberto Veronesi.”
Supplemental Material
Supplemental data for this article can be accessed on the pub
lisher’s website.
References
1. L€owenberg B, Downing JR, Burnett A. Acute myeloid
leukemia. N Engl J Med 1999; 341:1051-62;
PMID:10502596; http://dx.doi.org/10.1056/
NEJM199909303411407
2. Dash A, Gilliland DG. Molecular genetics of acute
myeloid leukaemia. Best Pract Res Clin Haematol
2001; 14:49-64; PMID:11355923; http://dx.doi.org/
10.1053/beha.2000.0115
3. Gilliland DG. Hematologic malignancies. Curr Opin
Hematol 2001; 8:189-91; PMID:11561153; http://dx.
doi.org/10.1097/00062752-200107000-00001
4. Tenen DG. Disruption of differentiation in human
cancer: AML shows the way. Nat Rev Cancer 2003;
3:89-101; PMID:12563308; http://dx.doi.org/
10.1038/nrc989
5. Koschmieder S, Rosenbauer F, Steidl U, Owens BM,
Tenen DG. Role of transcription factors C/EBPalpha
and PU.1 in normal hematopoiesis and in leukemia.
Int J Hematol 2005; 81:368-71; PMID:16158816;
http://dx.doi.org/10.1532/IJH97.05051
6. Nerlov C. C1487;EBPalpha mutations in acute mye-
loid leukaemias. Nat Rev Cancer 2004; 4:394-400;
PMID:15122210; http://dx.doi.org/10.1038/nrc1363
7. Kirstetter P, Schuster MB, Bereshchenko O, Moore S,
Dvinge H, Kurz E, Theilgaard-Monch K, Mansson R,
Pedersen TA, Pabst T. Modeling of C/EBPalpha
mutant acute myeloid leukemia reveals a common
expression signature of committed myeloid leukemia-
initiating cells. Cancer Cell 2008; 13:299-310;
PMID:18394553; http://dx.doi.org/10.1016/j.
ccr.2008.02.008
8. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gel-
metti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF,
Zamir I. Fusion proteins of the retinoic acid receptor-
alpha recruit histone deacetylase in promyelocytic leu-
kaemia. Nature 1998; 391:815-8; PMID:9486655;
http://dx.doi.org/10.1038/35901
9. Pabst T, Mueller BU, Harakawa N, Schoch C, Hafer-
lach T, Behre G, Hiddeman W, Zhang DE, Tenen
DG. AML1-ETO downregulates the granulocytic dif-
ferentiation factor C/EBPalpha in t(8;21) myeloid leu-
kemia. Nat Med 2001; 7:444-51; PMID:11283671;
http://dx.doi.org/10.1038/86515
10. Helbling D, Mueller BU, Timchenko NA, Hage-
meijer A, Jotterand M, Meyer-Monard S, Lister A,
Rowley JD, Huegli B, Fey MF, et al. The leukemic
fusion gene AML1-MDS1-EVI1 suppresses CEBPA
in acute myeloid leukemia by activation of Calreti-
culin. Proc Natl Acad Sci U S A 2004; 101:13312-
7; PMID:15326310; http://dx.doi.org/10.1073/
pnas.0404731101
11. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q. TAT-
mediated intracellular delivery of NPM-derived peptide
induces apoptosis in leukemic cells and suppresses leu-
kemogenesis in mice. Blood 2008; 112:2474-83;
PMID:18574026; http://dx.doi.org/10.1182/blood-
2007-12-130211
12. Liu X, Wang Y, Nakamura K, Kubo A, Hnatowich DJ.
Cell studies of a three-component antisense MORF/
tat/Herceptin nanoparticle designed for improved
tumor delivery. Cancer Gene Ther 2008; 15:126-32;
PMID:18084241; http://dx.doi.org/10.1038/sj.
cgt.7701111
13. Fujiki A, Imamura T, Sakamoto K, Kawashima S,
Yoshida H, Hirashima Y, Miyachi M, Yagyu S, Naka-
tani T, Sugiota K, et al. All-trans retinoic acid com-
bined with 5-aza-20-deoxycitidine induces C/EBPa
expression and growth inhibition in MLL-AF9-positive
leukemic cells. Biochem Biophys Res Commun 2012;
428:216-23; PMID:23063977; http://dx.doi.org/
10.1016/j.bbrc.2012.09.131
14. Iijima K, Honma Y, Niitsu N. Granulocytic differenti-
ation of leukemic cells with t(9;11)(p22;q23) induced
by all-trans-retinoic acid. Leuk Lymphoma 2004;
45:1017-24; PMID:15291362; http://dx.doi.org/
10.1080/1042819031000163887
15. Gu ZM, Wu YL, Zhou MY, Liu CX, Xu HZ, Yan H,
Zhao Y, Huang Y, Sun HD, Chen GQ. Pharicin B sta-
bilizes retinoic acid receptor-a and presents synergistic
differentiation induction with ATRA in myeloid leuke-
mic cells. Blood 2010; 116:5289-97;
PMID:20739655; http://dx.doi.org/10.1182/blood-
2010-02-267963
2588 Volume 14 Issue 16Cell Cycle
D
ow
nl
oa
de
d 
by
 [A
 Z
 U
SL
 R
eg
gio
 E
mi
lia
] a
t 0
7:2
0 2
5 A
ug
us
t 2
01
5 
16. Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, Lou J,
Yang B, He Q. Inhibition of all-trans-retinoic acid-
induced proteasome activation potentiates the differen-
tiating effect of retinoid in acute myeloid leukemia
cells. Mol Carcinog 2011; 50:24-35; PMID:20945414;
http://dx.doi.org/10.1002/mc.20687
17. Cassinat B, Zassadowski F, Ferry C, Llopis L, Bruck N,
Lainey E, Duong V, Cras A, Despouy G, Chourbagi
D. New role for granulocyte colony-stimulating factor-
induced extracellular signal-regulated kinase 1/2 in his-
tone modification and retinoic acid receptor a recruit-
ment to gene promoters: relevance to acute
promyelocytic leukemia cell differentiation. Mol Cell
Biol 2011; 31:1409-18; PMID:21262770; http://dx.
doi.org/10.1128/MCB.00756-10
18. Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet
M, Zhou DC, Grimwade D, Gallagher R, von Lindern
M, Waxman S. DNA methylation-independent loss of
RARA gene expression in acute myeloid leukemia.
Blood 2008; 111:2374-7; PMID:17993618; http://dx.
doi.org/10.1182/blood-2007-05-088344
19. Glasow A, Prodromou N, Xu K, von Lindern M,
Zelent A. Retinoids and myelomonocytic growth fac-
tors cooperatively activate RARA and induce human
myeloid leukemia cell differentiation via MAP kinase
pathways. Blood 2005; 105:341-9; PMID:15339853;
http://dx.doi.org/10.1182/blood-2004-03-1074
20. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC,
Wrobel MJ, Brunet JP, Subramanian A, Ross KN,
Reich M. The Connectivity Map: using gene-expres-
sion signatures to connect small molecules, genes, and
disease. Science 2006; 313:1929-35; PMID:17008526;
http://dx.doi.org/10.1126/science.1132939
21. Iorio F, Tagliaferri R, di Bernardo D. Identifying net-
work of drug mode of action by gene expression profil-
ing. J Comput Biol 2009; 16(2):241-51;
PMID:19183001; http://dx.doi.org/10.1089/
cmb.2008.10TT
22. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar
P, Ferriero R, Murino L,Tagliaferri R, Brunetti-Pierri
N, Isacchi A, et al. Discovery of drug mode of action
and drug repositioning from transcriptional responses.
Proc Natl Acad Sci U S A 2010; 107:14621-6;
PMID:20679242; http://dx.doi.org/10.1073/
pnas.1000138107
23. Zhang SD, Gant TW. sscMap: an extensible Java appli-
cation for connecting small-molecule drugs using gene-
expression signatures. BMC Bioinformatics 2009;
10:236; PMID:19646231; http://dx.doi.org/10.1186/
1471-2105-10-236
24. McArt DG, Bankhead P, Dunne PD, Salto-Tellez M,
Hamilton P, Zhang SD. cudaMap: a GPU accelerated
program for gene expression connectivity mapping.
BMC Bioinform 2013; 14:305; PMID:24112435;
http://dx.doi.org/10.1186/1471-2105-14-305
25. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich
RG, Davidsen SK. Gene expression profiling of multi-
ple histone deacetylase (HDAC) inhibitors: defining a
common gene set produced by HDAC inhibition in
T24 and MDA carcinoma cell lines. Mol Cancer Ther
2003; 2:151-63; PMID:12589032
26. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam
RW, Opferman JT, Sallan SE, den Boer ML, Pieters R.
Gene expression-based chemical genomics identifies
rapamycin as a modulator of MCL1 and glucocorticoid
resistance. Cancer Cell 2006; 10:331-42;
PMID:17010674; http://dx.doi.org/10.1016/j.
ccr.2006.09.006
27. Gheeya J, Johansson P, Chen QR, Dexheimer T, Meta-
feria B, Song YK, Wei JS, He J, Pommier Y, Khan J.
Expression profiling identifies epoxy anthraquinone
derivative as a DNA topoisomerase inhibitor. Cancer
Lett 2010; 293:124-31; PMID:20133050; http://dx.
doi.org/10.1016/j.canlet.2010.01.004
28. D’Arcy P, Brnjic S, Olofsson MH, Frykn€as M, Linds-
ten K, De Cesare M, Perego P, Sadeghi B, Hassan M,
Larsson R, Linder S. Inhibition of proteasome deubi-
quitinating activity as a new cancer therapy. Nat Med
2011; 17:1636-40; PMID:22057347; http://dx.doi.
org/10.1038/nm.2536
29. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox
DK, Malmberg SE, Alipour F, Shields RK, Adams
CM. mRNA expression signatures of human skeletal
muscle atrophy identify a natural compound that
increases muscle mass. Cell Metab 2011; 13:627-38;
PMID:21641545; http://dx.doi.org/10.1016/j.
cmet.2011.03.020
30. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S,
Chiang A, Morgan AA, Sarwal MM, Pasrucha PJ,
Butte AJ. Computational repositioning of the anticon-
vulsant topiramate for inflammatory bowel disease. Sci
Transl Med 2011; 3:96ra76; PMID:21849664; http://
dx.doi.org/10.1126/scitranslmed.3002648
31. Huang L, Zhao S, Frasor JM, Dai Y. An integrated bio-
informatics approach identifies elevated cyclin E2
expression and E2F activity as distinct features of
tamoxifen resistant breast tumors. PloS One 2011; 6:
e22274; PMID:21789246; http://dx.doi.org/10.1371/
journal.pone.0022274
32. Chen MH, Yang WL, Lin KT, Liu CH, Liu YW,
Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM,
et al. Gene expression-based chemical genomics identi-
fies potential therapeutic drugs in hepatocellular carci-
noma. PloS One 2011; 6:e27186; PMID:22087264;
http://dx.doi.org/10.1371/journal.pone.0027186
33. Ferrari-Amorotti G, Mariani SA, Novi C, Cattelani S,
Pecorari L, Corradini F, Soliera AR, Manzotti G, Fra-
gliasso V, Zhang Y, et al. The biological effects of C/
EBPalpha in K562 cells depend on the potency of the
N-terminal regulatory region, not on specificity of the
DNA binding domain. J Biol Chem 2010; 285:30837-
50; PMID:20659895; http://dx.doi.org/10.1074/jbc.
M110.128272
34. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L,
Gu LS, Whang ZY. Use of all-trans retinoic acid in the
treatment of acute promyelocytic leukemia. Blood
1988; 72:567-72; PMID:3165295
35. Castaigne S, Chomienne C, Daniel MT, Ballerini P,
Degos L. All-trans retinoic acid as a differentiation
therapy for acute promyelocytic leukemia. I. Clinical
results. Blood 1990; 76:1704-9; PMID:2224119
36. Lee MG, Wynder C, Schmidt DM, McCafferty DG,
Shiekhattar R. Histone H3 lysine 4 demethylation is a
target of nonselective antidepressive medications.
Chem Biol 2006; 13:563-7; PMID:16793513; http://
dx.doi.org/10.1016/j.chembiol.2006.05.004
37. Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente
Z, Soliera AR, Cattelani S, Manzotti G, Grisendi G,
Dominici M, Pieraccioli M, et al. Inhibiting interac-
tions of lysine demethylase LSD1 with snail/slug blocks
cancer cell invasion. Cancer Res 2013; 73:235-45;
PMID:23054398; http://dx.doi.org/10.1158/0008-
5472.CAN-12-1739
38. Gemelli C, Martello A, Montanari M, Zanocco-Mar-
ani T, Salsi V, Zappavigna V, Parenti S, Vignudelli T,
Selmi T, Ferrari S, Grande A. The Orosomucoid 1 pro-
tein is involved in the vitamin D – mediated macro-
phage de-activation process. Exp Cell Res 2013;
319:3201-13; PMID:23973664; http://dx.doi.org/
10.1016/j.yexcr.2013.08.017
39. Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF,
Koeffler HP. Restoration of C/EBPalpha expression in
a BCR-ABLC cell line induces terminal granulocytic
differentiation. J Biol Chem 2003; 278:52651-9;
PMID:14517214; http://dx.doi.org/10.1074/jbc.
M307077200
40. Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni
C, Iotti G, Cattelani S, Donato NJ, Calabretta B. Leu-
kemogenesis induced by wild-type and STI571-resis-
tant BCR/ABL is potently suppressed by C/EBPalpha.
Blood 2006; 108:1353-62; PMID:16670262; http://
dx.doi.org/10.1182/blood-2006-01-011833
41. Schenk T, Chen WC, G€ollner S, Howell L, Jin L,
Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills
K, et al. Inhibition of the LSD1 (KDM1A) demethy-
lase reactivates the all-trans-retinoic acid differentiation
pathway in acute myeloid leukemia. Nat Med 2012;
18:605-11; PMID:22406747; http://dx.doi.org/
10.1038/nm.2661
42. Blanpied TA, Clarke RJ, Johnson JW. Amantadine
inhibits NMDA receptors by accelerating channel clo-
sure during channel block. J Neurosci 2005; 25:3317-
22; http://dx.doi.org/10.1523/JNEUROSCI.4262-
04.2005
43. Forchap SL, Pirmohamed M, Clark RE. Release of
intracellular calcium primes chronic myeloid leukaemia
for tyrosine kinase inhibitor-induced apoptosis. Leuke-
mia 2012; 26:490-8; PMID:21886172; http://dx.doi.
org/10.1038/leu.2011.231
44. Komura T, Sakai Y, Honda M, Takamura T, Wada T,
Kaneko S. ER stress-induced impaired TLR signalling
and macrophage differentiation of human monocytes.
Cell Immunol 2013; 282:44-52; PMID:23665674;
http://dx.doi.org/10.1016/j.cellimm.2013.04.006
45. Issa LL, Leong GM, Eisman JA. Molecular mechanism
of vitamin D receptor action. Inflamm Res 1998;
47:451-75; PMID:9892040; http://dx.doi.org/
10.1007/s000110050360
46. Manfredini R, Trevisan F, Grande A, Tagliafico E,
Montanari M, Lemoli R, Visani G, Tura S, Ferrari S,
Ferrari S. Induction of a functional vitamin d receptor
in all-trans-retinoic acid-induced monocytic differenti-
ation of M2-type leukemic blast cells. Cancer Res
1999; 59:3803-11; PMID:10446999
47. Jurutka PW, Bartik L, Whitfield GK, Mathern DR,
Barthel TK, Gurerich M, Hsieh J-C, Kaczmarska M,
Haussler CA, Haussler MR. Vitamin D receptor: key
roles in bone mineral pathophysiology, molecular
mechanism of action, and novel nutritional ligands. J
Bone Miner Res 2007; 22(supplement 2):V1-V10
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S,
Ebert BL, Gillette MA, Paulovich A, Pomeroy SL,
Golub TR, Lander ES, et al. Gene set enrichment anal-
ysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci
2005;102:15545-50; PMID:16199517; http://dx.doi.
org/10.1073/pnas.0506580102
49. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F,
Riccardi C. A rapid and simple method for measuring
thymocyte apoptosis by propidium iodide staining and
flow cytometry. J Immunol Meth 1991; 139:271-
9http://dx.doi.org/10.1016/0022-1759(91)90198-O
50. Parenti S, Ferrarini F, Zini R, Montanari M, Losi L,
Canovi B, Ferrari S, Grande A. Mesalazine inhibits the
beta-catenin signalling pathway acting through the
upregulation of mu-protocadherin gene in colo-rectal
cancer cells. Aliment Pharmacol Ther 2010; 1:108-19;
http://dx.doi.org/10.1111/j.1365-2036.2009.04149.x
www.tandfonline.com 2589Cell Cycle
D
ow
nl
oa
de
d 
by
 [A
 Z
 U
SL
 R
eg
gio
 E
mi
lia
] a
t 0
7:2
0 2
5 A
ug
us
t 2
01
5 
